The single rarest genetic disorder ever recorded is ribose-5-phosphate isomerase deficiency, a metabolic condition first identified in 1999 in just one patient. For years, that single case stood alone in medical literature, making it the only known disease to affect exactly one person on Earth. While a small number of additional cases have since been investigated, it remains the standard example when geneticists discuss the outer edge of rarity. But the honest answer is more nuanced than a single name, because medicine is constantly discovering new conditions, and several ultra-rare disorders have fewer than 20 known patients worldwide.
Why “Rarest” Is a Moving Target
The U.S. Orphan Drug Act defines a rare disease as one affecting fewer than 200,000 Americans. That threshold captures roughly 10,000 distinct conditions, and combined, they affect an estimated 300 million people globally. Within that enormous category, “ultra-rare” diseases sit at the extreme end, sometimes with only a handful of patients ever documented.
The difficulty is that new ultra-rare genetic disorders are identified every year as genetic sequencing becomes more accessible. A condition with one known patient today might have five confirmed cases within a decade, simply because clinicians in other countries finally have the tools to test for it. So when you ask “what is the rarest,” the answer depends on the snapshot in time.
Ribose-5-Phosphate Isomerase Deficiency
This condition disrupts a step in how cells process sugars for energy and building DNA. The first and most thoroughly documented patient developed progressive damage to the brain’s white matter (leukoencephalopathy) along with nerve damage in the limbs. The enzyme that normally converts one sugar molecule into another during a key metabolic pathway simply doesn’t work properly, causing toxic byproducts to accumulate.
Because so few people have ever been diagnosed, almost everything known about the condition comes from that original case report published in the American Journal of Human Genetics. There is no approved treatment. Management focuses on monitoring neurological symptoms and supporting quality of life. The rarity itself is the central obstacle: with virtually no patient population, there is no clinical trial infrastructure and very little research funding.
Other Disorders With Fewer Than 20 Patients
Ribose-5-phosphate isomerase deficiency isn’t the only condition sitting at the far end of the rarity spectrum. Loucks-Innes syndrome, caused by mutations in a gene involved in building a specific protein modification called diphthamide, has fewer than 20 reported cases worldwide. Children with this condition typically have intellectual disability, short stature, distinctive facial features, sparse hair, thin skin, and abnormal nails. Some also develop heart abnormalities and hearing loss. Cases have been identified across multiple ethnicities, suggesting the condition isn’t confined to one population but is simply too rare for most clinicians to recognize.
Fields-Barker syndrome, Ogden syndrome, and several other named genetic conditions also exist in the single-digit or low double-digit patient range. Many of these were only identified in the last 10 to 15 years, and their patient counts will likely grow as awareness and testing improve.
Why These Conditions Go Undiagnosed for Years
The average time to diagnosis for any rare disease in Europe is 4.7 years. For the rarest conditions, that timeline stretches much longer. Patients who see eight or more different doctors during their diagnostic journey wait an average of 9.6 years, and nearly half of them experience significant delays. Misdiagnosis compounds the problem: being given at least one wrong diagnosis more than doubles the odds of a prolonged search for answers.
Part of the issue is pattern recognition. A pediatrician who has never encountered a condition with 15 known cases worldwide has no clinical frame of reference. The child’s symptoms, often a combination of developmental delay, unusual facial features, and organ involvement, can mimic dozens of more common syndromes. Without genetic testing, there’s no reliable way to distinguish one ultra-rare condition from another.
How Genetic Sequencing Changed the Picture
Whole-exome sequencing, which reads the protein-coding portions of a person’s DNA, now provides a diagnosis in roughly 40 to 50% of children with suspected genetic disorders. A large study of over 13,000 individuals found a 41% success rate, and smaller studies have reported yields as high as 51%. That means for about half of families stuck in a diagnostic odyssey, a single blood draw and sequencing run can end years of uncertainty.
This technology is also why the list of known rare diseases keeps growing. Twenty years ago, many of these conditions simply had no name. A child would be described as having “global developmental delay of unknown cause.” Now, sequencing can pinpoint the exact gene variant responsible, which sometimes turns out to be a mutation no one has ever documented before. That’s how new ultra-rare disorders enter the medical literature: one patient at a time, one case report at a time.
The Treatment Gap
Only about 5% of the nearly 10,000 identified rare diseases have an FDA-approved treatment. For ultra-rare conditions with fewer than 20 patients, the number drops effectively to zero. Pharmaceutical development requires clinical trials, and clinical trials require enough patients to measure whether a drug works. When the entire global patient population fits in a single room, traditional drug development models break down.
What this means in practice is that families dealing with the rarest genetic disorders rely on symptom management rather than targeted therapies. A child with Loucks-Innes syndrome might receive hearing aids, growth monitoring, and educational support, but there is no drug designed to correct the underlying enzyme defect. Gene therapy holds theoretical promise for some of these conditions, but bringing a therapy from concept to clinic for a disorder with 15 known patients requires funding models that don’t yet exist at scale.
For the roughly 300 million people worldwide living with some form of rare disease, the collective burden is enormous even though each individual condition is uncommon. The rarest of the rare, like ribose-5-phosphate isomerase deficiency, represent the extreme case of a systemic challenge: conditions so uncommon that diagnosis, research, and treatment all depend on a handful of dedicated specialists noticing that something doesn’t fit the usual patterns.